For instance, reduced serum C5a levels or suboptimal complement activation due to C5 single nucleotide polymorphisms are independent risk factors for poor outcomes in patients with candidemia [33], this helps explain the susceptibility of patients treated with avacopan to fungal infections. This evidence concerns the gene C5AR1 and fungal infectious disease.